Published in Science on February 03, 2006
Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med (2015) 4.85
Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol (2010) 3.77
uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol (2007) 1.84
Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood (2010) 1.82
Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta (2011) 1.73
SLEEPLESS, a Ly-6/neurotoxin family member, regulates the levels, localization and activity of Shaker. Nat Neurosci (2009) 1.27
Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol (2006) 1.25
Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol (2008) 1.23
Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem (2010) 1.14
Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction. J Biol Chem (2011) 1.09
Structural basis for EGFR ligand sequestration by Argos. Nature (2008) 1.08
Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis (2011) 1.04
A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR). J Biol Chem (2012) 1.03
Role of urokinase receptor in tumor progression and development. Theranostics (2013) 1.00
Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. Bioorg Med Chem (2013) 1.00
Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis (2010) 0.94
Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor. J Biol Chem (2011) 0.94
The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target. Theranostics (2013) 0.94
Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion. ACS Chem Biol (2011) 0.94
The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization. Am J Physiol Cell Physiol (2008) 0.93
Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM). PLoS One (2014) 0.92
Pericellular proteolysis in cancer. Genes Dev (2014) 0.92
Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor. World J Nephrol (2013) 0.92
The urokinase receptor homolog Haldisin is a novel differentiation marker of stratum granulosum in squamous epithelia. J Histochem Cytochem (2013) 0.90
A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor. J Biol Chem (2008) 0.90
The urokinase plasminogen activator receptor promotes efferocytosis of apoptotic cells. J Biol Chem (2009) 0.88
siRNA against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats. Acta Pharmacol Sin (2012) 0.88
Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist. Theranostics (2013) 0.88
Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications. Clin Physiol Funct Imaging (2013) 0.87
A novel tumor targeting drug carrier for optical imaging and therapy. Theranostics (2014) 0.86
Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding. RNA (2010) 0.85
Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR). Bioconjug Chem (2009) 0.84
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC Cancer (2014) 0.83
A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance. J Biol Chem (2010) 0.81
Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesis. J Histochem Cytochem (2011) 0.81
Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence. Oncotarget (2014) 0.80
A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction. ACS Chem Biol (2015) 0.79
The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells. Oncotarget (2016) 0.79
NMR solution structure of the neurotrypsin Kringle domain. Biochemistry (2008) 0.78
Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance. Biochem J (2016) 0.78
Challenges for drug discovery - a case study of urokinase receptor inhibition. Comb Chem High Throughput Screen (2009) 0.77
The High Affinity Binding Site on Plasminogen Activator Inhibitor-1 (PAI-1) for the Low Density Lipoprotein Receptor-related Protein (LRP1) Is Composed of Four Basic Residues. J Biol Chem (2015) 0.76
Ligand binding alters dimerization and sequestering of urokinase receptors in raft-mimicking lipid mixtures. Biophys J (2014) 0.76
Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor. ChemMedChem (2013) 0.76
Lanthanides: Applications in Cancer Diagnosis and Therapy. J Med Chem (2016) 0.76
Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2. Am J Physiol Heart Circ Physiol (2013) 0.76
X-ray sequence and crystal structure of luffaculin 1, a novel type 1 ribosome-inactivating protein. BMC Struct Biol (2007) 0.76
Unwinding focal segmental glomerulosclerosis. F1000Res (2017) 0.75
Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years. Hypertens Res (2015) 0.75
Leach-proof magnetic thrombolytic nanoparticles and coatings of enhanced activity. Sci Rep (2016) 0.75
Biophysical Mechanisms Mediating Fibrin Fiber Lysis. Biomed Res Int (2017) 0.75
DOT corrected fluorescence molecular tomography using targeted contrast agents for small animal tumor imaging. J Xray Sci Technol (2013) 0.75
Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography. Data Brief (2015) 0.75
Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements. AAPS PharmSciTech (2015) 0.75
Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models. J Biomed Sci (2016) 0.75
Proteases Revisited: Roles and Therapeutic Implications in Fibrosis. Mediators Inflamm (2017) 0.75
Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo. Int J Nanomedicine (2015) 0.75
Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains. J Biol Chem (2012) 0.75
Effects of allopurinol on exercise-induced muscle damage: new therapeutic approaches? Cell Stress Chaperones (2014) 0.75
Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem (2004) 15.51
Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins (2010) 9.43
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
How fast-folding proteins fold. Science (2011) 6.24
Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature (2011) 5.35
A hierarchical approach to all-atom protein loop prediction. Proteins (2004) 5.18
Mechanisms of thrombus formation. N Engl J Med (2008) 4.67
Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med (2002) 4.54
The dynamic process of β(2)-adrenergic receptor activation. Cell (2013) 4.09
Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature (2012) 3.83
Long-timescale molecular dynamics simulations of protein structure and function. Curr Opin Struct Biol (2009) 3.81
Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med (2003) 3.61
Mechanism of voltage gating in potassium channels. Science (2012) 3.24
How robust are protein folding simulations with respect to force field parameterization? Biophys J (2011) 3.00
Biomolecular simulation: a computational microscope for molecular biology. Annu Rev Biophys (2012) 2.85
Identification of two distinct inactive conformations of the beta2-adrenergic receptor reconciles structural and biochemical observations. Proc Natl Acad Sci U S A (2009) 2.77
Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell (2012) 2.67
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A (2009) 2.55
Activation mechanism of the β2-adrenergic receptor. Proc Natl Acad Sci U S A (2011) 2.53
PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des (2006) 2.53
Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell (2013) 2.49
Principles of conduction and hydrophobic gating in K+ channels. Proc Natl Acad Sci U S A (2010) 2.47
Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci U S A (2011) 2.44
High-resolution crystal structure of human protease-activated receptor 1. Nature (2012) 2.44
Thrombus formation in vivo. J Clin Invest (2005) 2.38
Gaussian split Ewald: A fast Ewald mesh method for molecular simulation. J Chem Phys (2005) 2.32
Architecture and membrane interactions of the EGF receptor. Cell (2013) 2.29
Systematic validation of protein force fields against experimental data. PLoS One (2012) 2.29
A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest (2008) 2.26
A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci U S A (2008) 2.18
Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood (2004) 2.16
How does a drug molecule find its target binding site? J Am Chem Soc (2011) 2.13
Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood (2006) 2.06
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res (2009) 2.04
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol (2003) 2.03
Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2). Proc Natl Acad Sci U S A (2010) 1.96
Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci U S A (2006) 1.95
Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure (2008) 1.93
Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost (2003) 1.91
Microsecond molecular dynamics simulation shows effect of slow loop dynamics on backbone amide order parameters of proteins. J Phys Chem B (2008) 1.90
How I treat heparin-induced thrombocytopenia. Blood (2012) 1.85
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation (2008) 1.84
Mechanism of Na+/H+ antiporting. Science (2007) 1.79
Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest (2007) 1.76
Tet3 CXXC domain and dioxygenase activity cooperatively regulate key genes for Xenopus eye and neural development. Cell (2012) 1.76
Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci U S A (2012) 1.70
β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood (2011) 1.69
Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nat Struct Biol (2003) 1.68
Nuclear translocation of urokinase-type plasminogen activator. Blood (2008) 1.66
Atomic-level description of ubiquitin folding. Proc Natl Acad Sci U S A (2013) 1.65
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res (2009) 1.64
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood (2004) 1.63
Post-transcriptional regulation of urokinase-type plasminogen activator receptor expression in lipopolysaccharide-induced acute lung injury. Am J Respir Crit Care Med (2008) 1.62
Wild bird migration across the Qinghai-Tibetan plateau: a transmission route for highly pathogenic H5N1. PLoS One (2011) 1.62
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood (2005) 1.59
Dynamic antibody-binding properties in the pathogenesis of HIT. Blood (2012) 1.59
Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature (2013) 1.59
Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci U S A (2008) 1.58
Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res (2006) 1.58
Differential angiogenic regulation of experimental colitis. Am J Pathol (2006) 1.55
Transdisciplinary cardiovascular and cancer health disparities training: experiences of the centers for population health and health disparities. Am J Public Health (2015) 1.54
Platelet PECAM-1 inhibits thrombus formation in vivo. Blood (2005) 1.53
Single-chain urokinase alone or complexed to its receptor in tetracycline-induced pleuritis in rabbits. Am J Respir Crit Care Med (2002) 1.53
Refinement of protein structure homology models via long, all-atom molecular dynamics simulations. Proteins (2012) 1.52
Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest (2012) 1.51
Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. Blood (2012) 1.50
Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood (2004) 1.50
The role of ligands on the equilibria between functional states of a G protein-coupled receptor. J Am Chem Soc (2013) 1.48
PSGL-1 participates in E-selectin-mediated progenitor homing to bone marrow: evidence for cooperation between E-selectin ligands and alpha4 integrin. Blood (2003) 1.46
Computational design and experimental testing of the fastest-folding β-sheet protein. J Mol Biol (2010) 1.46
Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J Leukoc Biol (2005) 1.46
Structure and dynamics of an unfolded protein examined by molecular dynamics simulation. J Am Chem Soc (2012) 1.46
Protein folding kinetics and thermodynamics from atomistic simulation. Proc Natl Acad Sci U S A (2012) 1.46
Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest (2012) 1.45
Exploring atomic resolution physiology on a femtosecond to millisecond timescale using molecular dynamics simulations. J Gen Physiol (2010) 1.44
Endothelium-derived but not platelet-derived protein disulfide isomerase is required for thrombus formation in vivo. Blood (2010) 1.43